Treating Small-Cell Lung Cancer (SCLC) in the Relapsed/Refractory Setting: Giving Patients a Voice About Second-Line Therapy

---

ONLINE

Friday, September 13, 2024, 12:00 AM - Saturday, September 13, 2025, 11:59 PM


AMA PRA Category 1 Credits™ (1.00 hours), ANCC - Nursing Contact Hour(s) (1.00 hours), Non-Physician Attendance (1.00 hours)

SCLC is aggressive in nature with a high recurrence rate following initial treatment and a propensity to become resistant to conventional therapies. Early detection is critical, but many patients are diagnosed at an advanced stage where prognosis is poor. Progress in the second-line setting offers new hope for improving patient outcomes, but the rapid pace at which these advances are occurring present challenges for effectively integrating novel therapies into patient care. In fact, research shows that oncologists may not be offering second-line therapies to patients with SCLC despite good functional status.

1. Outline evidence-based diagnostic approaches surrounding small-cell lung cancer (SCLC)
2. Assess recent safety and efficacy data of new and emerging approaches for the treatment of refractory and relapsed SCLC
3. Integrate novel therapeutic agents and approaches into current and evolving SCLC treatment paradigms in the relapsed/refractory setting based on evolving clinical trial findings
4. Discuss the pervasive healthcare disparities that disproportionately impact underserved patient populations, particularly in the context of SCLC

In support of improving patient care, The University of Texas MD Anderson Cancer Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Credit Designations

The University of Texas MD Anderson Cancer Center designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

The University of Texas MD Anderson Cancer Center designates this enduring material will award 1.0 Nursing Contact Hours.

View the accessibility policy for The University of Texas MD Anderson Cancer Center.

 

The University of Texas MD Anderson Cancer Center complies with all requirements of the identified accrediting body  (ACCME, ANCC, ACPE). Disclosure of speakers, faculty members, planning committee members and their commercial relationships will be shared with learners prior to the educational activity.

Mitigation of Relevant Financial Relationships

The University of Texas MD Anderson Cancer Center adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all financial relationships with ineligible companies (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

This program is supported by an independent medical education grant from Jazz Pharmaceuticals.